In recent years, there has been growing evidence of the potential therapeutic benefits of PDIA3 inhibition in various cancers, including clear cell renal cell carcinoma [41], drug-resistant ovarian cancer [42], breast cancer [43,44], hepatocellular carcinoma [45] and in multidrug-resistant gastric cancer [46]. This evidence concerns the gene PDIA3 and cancer.